CLINICAL ROLE -
Managing Tardive Dyskinesia With VMAT2 Inhibitors in Clinical Practice
VMAT2 inhibitors can improve movement symptoms.
Community Behavioral Health Clinics Can Be Instrumental in Switching Patients to Long-Acting Injectable Antipsychotics
Preliminary Data Show Over One-Third of Patients With Psychiatric Diagnoses Visit ED After GLP-1 Initiation
A recent study reveals a significant number of patients with psychiatric histories experience emergency visits after starting glucagon-like peptide-1 (GLP-1) medications, raising safety concerns.
Trial Data Show Long-Term Safety, Efficacy of Xanomeline/Trospium for Schizophrenia
New trials reveal xanomeline and trospium effectively alleviate schizophrenia symptoms, offering a novel treatment option with minimal adverse effects.
Research Identifies Need for Increased Evidence-Based Use of Buspirone
New research highlights the need for evidence-based buspirone use in psychiatric settings, revealing high off-label prescriptions and suboptimal dosing practices.
Prescription Digital Therapeutics for Mental Health: Effectiveness, Challenges, and Future Trends
The use of artificial intelligence and real-time symptom monitoring integrate effectiveness of prescription digital therapeutics for mental health issues
The Role of Pharmacists in Identifying and Managing Psychiatric Medication Overdoses
Pharmacists play a key role in psychiatric medication overdose situations
Developing Novel Treatments for Schizophrenia: Opportunities and Challenges in Personalizing Care
Exploring challenges and opportunities in developing personalized treatments for schizophrenia
Psychedelic Medicine Could Fill Care Gap in Psychiatric Care
However, psychedelic medicine has a variety of barriers, including historical perception, access challenges, legal obstacles, and ethical questions.
Digital Therapeutics Might Address Gaps in Care for Mental Health Patients
Pharmacists should be well educated on prescription digital therapeutics to better educate patients on software in comparison to traditional pharmacological products.
Understanding Social Determinants of Health and Their Impact on Mental Illness Treatment
Pharmacists can address social determinants to improve patient well-being and treatment.
Managing Insomnia in Special Populations and Treatment-Resistant Cases
Challenges in treating insomnia in special groups and resistant cases, and ways for pharmacists to improve outcomes.
Anticholinergic Medications in Older Adults and Strategies for Safe Deprescribing
Linking strong anticholinergic medications to increased risk of dementia in older adults
Pharmacists Improve Quality of Depression Care at Patient, Community Levels
Social determinants of health can worsen mental health disorders such as depression, but the effect of depression can also negatively impact social determinants of health.
Expert: New Schizophrenia Treatments Targeting Muscarinic Receptors
Potential for integration into care and future advancements for gaps in current schizophrenia treatments
More Research Needed for Treatment of Clozapine-Resistant Schizophrenia
Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.
Contraceptive Considerations and Communication Strategies for Patients with Psychiatric Conditions
Guidance on evaluating contraceptive options for patients with psychiatric conditions
Patient Preferences Play Essential Part in Contraceptive Care
Although there are medical considerations for patients with psychiatric conditions, prescribers must consider patient preference to increase adherence and effectiveness of contraception.
Novel Approaches to Treating the Full Spectrum of Schizophrenia Symptoms, Modulating Dopamine and Glutamate Neurotransmission
New approaches for treating all schizophrenia symptoms by modulating dopamine and glutamate in non-traditional ways.
Pharmacists Facilitate Harm Reduction for Patients With Anxiety Using Cannabis
Data for generalized anxiety disorders and cannabis use is scarce, but pharmacists can help educate patients on potential benefits and risks of cannabis usage.
Expert: The Evolving Landscape of Pharmacologic Research and Clinical Management of Symptoms in Borderline Personality Disorder
Expert perspective on current research, treatment approaches, and clinical considerations for pharmacologic management of borderline personality disorder
Exploring Treatment Options for Patients with Treatment-Resistant Schizophrenia
Potential adjunctive and novel treatment options based on a patient's specific symptoms and clinical factors are being explored to treat treatment-resistant schizophrenia
Novel Drugs Targeting Different Pathways Show Promise in Schizophrenia
Developments in glycine transporter type 1 inhibitors, D-amino acid oxidase inhibitors, and phosphodiesterase inhibitors are pushing schizophrenia research forward.
5 Key Sessions at the American Association of Psychiatric Pharmacists Annual Meeting 2024
Pharmacy Times will be at the American Association of Psychiatric Pharmacists (AAPP) Annual Meeting in Orlando, Florida from April 7 to April 10, 2024.
